Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population

Scientific Reports
Cai-Mei ZhengYuh-Feng Lin

Abstract

It remains unclear how different uses of angiotensin-converting inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) influence the progression of chronic kidney disease (CKD). This study explored CKD progression in a multicentre, longitudinal cohort study that included 2639 patients with CKD stage 1-5 and hypertension. Patients treated with ACEI or ARB for ≥90 days during a 6-mo period comprised the study group, or no treatment, comprised the control group. The study group was subdivided on the basis of treatment: ACEI monotherapy or ARB monotherapy. Progression of renal deterioration was defined by an average eGFR decline of more than 5 mL/min/1.73 m2/yr or the commencement of dialysis. With at least 1-year follow up, a progression of renal deterioration was demonstrated in 29.70% of the control group and 25.09% of the study group. Patients in the study group had significantly reduced progression of CKD with adjusted odds ratio 0.79 (95% confidence interval: 0.63-0.99). However, when ACEI monotherapy and ARB monotherapy were analyzed separately, none of their associations with CKD progression was statistically significant. In conclusion, ACEI or ARB monotherapy may retard the deterioration of renal function among patient...Continue Reading

References

Oct 1, 1994·BMJ : British Medical Journal·T HannedoucheJ M Suo
May 3, 2000·Kidney International·M W Taal, B M Brenner
May 1, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·A J LewingtonJ Walls
Sep 5, 2001·Kidney International·T H JafarUNKNOWN AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Feb 3, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Robert C AtkinsEdmund J Lewis
Mar 9, 2005·Kidney International. Supplement·Philip Kam-Tao LiUNKNOWN Participants of ISN Consensus Workshop on Prevention of Progression of Renal Disease
Aug 18, 2005·European Heart Journal·Ruud M A van de WalAdriaan A Voors
Dec 13, 2005·International Journal of Cardiology·R M A van de WalA A Voors
Jun 27, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Martin MacKinnonHeather D Clark
Dec 13, 2006·Renal Failure·Nelson MazzuchiAlejandro Ferreiro
Dec 23, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Hsin-Wei KuoChun-Yuh Yang
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Yoshihiko KannoHiromichi Suzuki
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
May 13, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Fausta CatapanoGiuseppe Conte
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Aug 16, 2011·Lancet·Andrew S Levey, Josef Coresh
Dec 30, 2011·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Allan J CollinsLawrence Agodoa
Nov 12, 2013·The New England Journal of Medicine·Linda F FriedUNKNOWN VA NEPHRON-D Investigators
Mar 22, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Lesley A InkerHarold I Feldman

❮ Previous
Next ❯

Citations

Apr 25, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Martha Sahylí Ortega PijeiraEmerson Soares Bernardes
Jul 27, 2021·KI Reports·Peter StenvinkelBradley A Warady

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.